REPRIEVE final results: What does it mean for guidelines in low‐ and middle‐income countries?

Abstract Introduction The REPRIEVE study demonstrated significant reductions in major adverse cardiovascular events (MACE) with pitavastatin among people living with HIV (PWH) with low to moderate cardiovascular risk. Most MACE events occurred in higher‐income countries, raising important considerat...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Simiso Sokhela, Jennifer M. Manne‐Goehler, Samanta Lalla‐Edward, Mark J. Siedner, Mohammed K. Ali, Andrew Hill, Aaloke Mody, Anton Pozniak, Jeremy Nel, W. D. Francois Venter
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2025-06-01
Serie:	Journal of the International AIDS Society
Soggetti:	cardiovascular HIV MACE pitavastatin REPRIEVE statin
Accesso online:	https://doi.org/10.1002/jia2.26525
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!